CollPlant Biotechnologies (NASDAQ:CLGN) Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.
CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues. These bioinks serve as scaffolds to support cell growth and tissue formation, targeting indications such as cartilage repair, orthopedic implants and breast reconstruction. The company’s preclinical pipeline extends into areas like tendon and ligament engineering, leveraging its collagen platform to address unmet needs in regenerative therapy.
Founded in 2009 and headquartered in Rehovot, Israel, CollPlant maintains operations in the United States with offices in Bridgewater, New Jersey. The company has secured CE Mark approvals for several products in Europe and is pursuing additional regulatory clearances worldwide. Through strategic collaborations and licensing agreements, CollPlant aims to expand its global footprint across North America, Europe and Asia, partnering with device manufacturers and research institutions to accelerate product development.
Under the leadership of President and Chief Executive Officer Yehiel Tal, CollPlant’s management team combines expertise in biotechnology, medical devices and pharmaceutical development. The company continues to invest in research, manufacturing capacity and strategic partnerships to advance its vision of providing sustainable, high-quality collagen solutions for the regenerative medicine market.
